复发性心肌梗死患者较原发性心肌梗死患者造血炎症反应降低且预后更差
本研究纳入105例患者,用18F-FDG PET评估原发性心肌梗死(PMI)、复发性心肌梗死(RMI)与慢性稳定型心绞痛(CSA)患者的造血炎症激活及预后。结果显示骨髓靶本比在PMI组最高、RMI组居中、CSA组最低(P<0.001);RMI组瘢痕更大、左室射血分数显著降低、收缩末期容积增大,且中位随访16.6个月时无主要不良心脏事件生存率低于PMI和CSA组(P=0.026)。
要点
- 骨髓靶本比在PMI组最高、RMI组居中、CSA组最低(P<0.001)。
- RMI组较PMI和CSA组瘢痕更大、左室射血分数显著降低、收缩末期容积增大(P<0.05)。
- 中位随访16.6个月,RMI组无主要不良心脏事件生存率低于PMI和CSA组(P=0.026)。
核心结论
- 与PMI相比,RMI的造血炎症激活相对降低;RMI患者随后出现更大的心肌瘢痕、更差的心功能、加重的心脏重构及更差的预后。
研究设计与样本
- 共纳入105例患者(88例男性;年龄60.1±9.7岁),分为PMI组(n=45)、RMI组(n=30)和CSA组(n=30),采用18F-FDG PET评估造血炎症激活并随访预后。
主要发现
- 骨髓靶本比(TBRBM)在PMI组最高、RMI组居中、CSA组最低(P<0.001)。
- RMI组较PMI和CSA组分别显示更大的瘢痕、左室射血分数显著降低和收缩末期容积增大(P<0.05)。
- TBRBM与主动脉靶本比(TBRaorta)呈显著正相关(P<0.001)。
- 中位随访16.6个月,RMI组无主要不良心脏事件累积生存率低于PMI和CSA组(P=0.026)。
关键数值与推荐
- 骨髓靶本比(TBRBM)在PMI组(n=45)最高、RMI组(n=30)居中、CSA组(n=30)最低(P<0.001)。
- RMI组较PMI和CSA组瘢痕更大、左室射血分数显著降低、收缩末期容积增大(P<0.05)。
- TBRBM与TBRaorta呈显著正相关(P<0.001)。
- 中位随访16.6个月,RMI组无主要不良心脏事件累积生存率低于PMI和CSA组(P=0.026)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent myocardial infarction (RMI) portends an unfavorable outcome, which might be related to diminished hematopoietic-inflammatory activation. We aimed to investigate the hematopoietic-inflammatory activation and the outcome in categorized patients with primary myocardial infarction (PMI) versus RMI as well as chronic stable angina (CSA) by 18F-FDG PET. RESULTS: A total of 105 patients (88 males; 60.1 ± 9.7 years) were included. Target-to-background ratio of bone marrow (TBRBM) was highest in the PMI group (n = 45), intermediate in the RMI group (n = 30), and lowest in the CSA group (n = 30) (P < 0.001). RMI group exhibited larger scar, significantly reduced left ventricular ejection fraction, and enlarged end systolic volume in comparison with the PMI and CSA groups, respectively (P < 0.05). Additionally, there was a significantly positive correlation between TBRBM and TBRaorta (P < 0.001). The cumulative major adverse cardiac events free survival of patients in the RMI group was lower than that in the PMI and CSA groups during a median follow-up of 16.6 months (P = 0.026). CONCLUSIONS: RMI conferred relatively decreased hematopoietic-inflammatory activation compared with PMI. Patients with RMI presented subsequent enlarged myocardial scar, worsened cardiac dysfunction, aggravated remodeling, and worse outcomes than that in PMI patients.
引用
- Lu Y, Meng J, Yun M, et al. Reduced hematopoietic-inflammatory response and worse outcomes in patients with recurrent myocardial infarction in comparison with primary myocardial infarction. EJNMMI Res. 2023. PMID: 37749412. doi:10.1186/s13550-023-01035-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。